

# PE-01BFG99H-P

## AKT1 (14-20) Peptide Powder

9-mer immunogen peptide based on Akt1 (PKBa)



# KINEXUS

Address: 8755 Ash Street, Suite 1  
Vancouver, British Columbia,  
Canada V6P 6T3

Email: [info@kinexus.ca](mailto:info@kinexus.ca)  
Phone: 604-323-2547

### Target Protein

<b>Name Long:</b>	RAC-alpha serine/threonine-protein kinase
<b>Name Alias:</b>	AKT; Akt1; AKT1 kinase; C-AKT; Kinase Akt1; PKB; PKB-alpha; PRKBA; V-akt murine thymoma viral oncogene 1; Protein kinase B; RAC; RAC-alpha serine,threonine kinase; RAC-alpha serine/threonine kinase; RAC-PK-alpha; PKBA; hCG_96740; AKT1_NEW; AKT; MGC99656; CCDS9994; B0LPE5; B2RAM5; B3KVH4; B3KXD7; B7Z5R1; Q9BV07; ENSG00000142208
<b>Species Origin:</b>	Human
<b>UniProt ID:</b>	P31749

### Peptide Structure

<b>Peptide Name:</b>	AKT1 (14-20)
<b>Peptide Origin:</b>	In the N-terminus of the kinase. The E17K is a common mutation in Akt1 in human cancers.
<b>Peptide Sequence Location:</b>	K14-K20
<b>Peptide Sequence:</b>	KRGKYIK(bA)C
<b>Peptide N-Terminus:</b>	Free amino
<b>Peptide C-Terminus:</b>	Amide
<b>Peptide Modifications Other:</b>	None; Includes beta-alanine-cysteine at C-terminus for coupling to KLH or thio-agarose

### Production

<b>Peptide Production Method:</b>	Solid-phase peptide synthesis
<b>Calculated Peptide Mass:</b>	1065.6
<b>Observed Peptide Mass:</b>	1065.3
<b>% Peptide Purity:</b>	97.7
<b>Peptide Appearance:</b>	White powder
<b>Peptide Form:</b>	Solid
<b>Peptide Solubility:</b>	Dissolve in 50 µl DMSO and dilute to desired concentration with water or aqueous buffer
<b>Lot Number:</b>	KMP01CAH-16
<b>Amount:</b>	1 mg
<b>Storage Conditions:</b>	Frozen at -20°C
<b>Storage Stability:</b>	Over 1 year at -20°C

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit [www.kinexusproducts.ca](http://www.kinexusproducts.ca) or contact us at 1-866-KINASES (546-2737)